Similar articles

• [Efficacy of tumor necrosis factor-alpha inhibitors in fistulising perianal Crohn's disease].

  Bor R, Farkas K, Bálint A, Szűcs M, Abrahám S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnár T. Bor R, et al. Orv Hetil. 2013 Dec 8;154(49):1943-8. doi: 10.1556/OH.2013.29770. Orv Hetil. 2013. PMID: 24292112 Hungarian.
• Prediction of response to infliximab in Crohn's disease.

  Chaudhary R, Ghosh S. Chaudhary R, et al. Dig Liver Dis. 2005 Aug;37(8):559-63. doi: 10.1016/j.dld.2005.04.002. Dig Liver Dis. 2005. PMID: 15893967 Review. No abstract available.
• Management of fistulas in patients with Crohn's disease: antibiotic to antibody.

  Paré P. Paré P. Can J Gastroenterol. 2001 Nov;15(11):751-6. doi: 10.1155/2001/697143. Can J Gastroenterol. 2001. PMID: 11727005 Review.
• Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy.

  Papamichael K, Cheifetz AS. Papamichael K, et al. World J Gastroenterol. 2017 Sep 14;23(34):6197-6200. doi: 10.3748/wjg.v23.i34.6197. World J Gastroenterol. 2017. PMID: 28974885 Free PMC article.
• ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment.

  Torres J, Bonovas S, Doherty G, Kucharzik T, Gisbert JP, Raine T, Adamina M, Armuzzi A, Bachmann O, Bager P, Biancone L, Bokemeyer B, Bossuyt P, Burisch J, Collins P, El-Hussuna A, Ellul P, Frei-Lanter C, Furfaro F, Gingert C, Gionchetti P, Gomollon F, González-Lorenzo M, Gordon H, Hlavaty T, Juillerat P, Katsanos K, Kopylov U, Krustins E, Lytras T, Maaser C, Magro F, Marshall JK, Myrelid P, Pellino G, Rosa I, Sabino J, Savarino E, Spinelli A, Stassen L, Uzzan M, Vavricka S, Verstockt B, Warusavitarne J, Zmora O, Fiorino G. Torres J, et al. J Crohns Colitis. 2020 Jan 1;14(1):4-22. doi: 10.1093/ecco-jcc/jjz180. J Crohns Colitis. 2020. PMID: 31711158 No abstract available.